-
公开(公告)号：US07563441B2
公开(公告)日：2009-07-21
申请号：US11102403
申请日：2005-04-08
申请人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
发明人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2854 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S435/81
摘要： This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
摘要翻译： 本发明涉及抗P-选择素抗体，特别涉及含有源自人源的Fc部分并且不结合补体因子C1q的抗P-选择素抗体及其变体。 这些抗体具有新的和本发明的性质，为患有严重肢体缺血或外周动脉闭塞性疾病（CLI / PAOD）的患者带来益处。
-
公开(公告)号：US20050226876A1
公开(公告)日：2005-10-13
申请号：US11102403
申请日：2005-04-08
申请人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
发明人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
CPC分类号： C07K16/2854 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S435/81
摘要： This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
摘要翻译： 本发明涉及抗P-选择素抗体，特别涉及含有源自人源的Fc部分并且不结合补体因子C1q的抗P-选择素抗体及其变体。 这些抗体具有新的和本发明的性质，为患有严重肢体缺血或外周动脉闭塞性疾病（CLI / PAOD）的患者带来益处。
-
3.发明授权Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies 有权用抗P-选择蛋白抗体抑制P-选择素与PSGL-1结合的方法公开(公告)号：US07824684B2
公开(公告)日：2010-11-02
申请号：US12768150
申请日：2010-04-27
申请人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
发明人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2854 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S435/81
摘要： This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
摘要翻译： 本发明涉及抗P-选择素抗体，特别涉及含有源自人源的Fc部分并且不结合补体因子C1q的抗P-选择素抗体及其变体。 这些抗体具有新的和本发明的性质，为患有严重肢体缺血或外周动脉闭塞性疾病（CLI / PAOD）的患者带来益处。
-
公开(公告)号：USRE43568E1
公开(公告)日：2012-08-07
申请号：US13187586
申请日：2011-07-21
申请人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan Van de Winkel , Martine Van Vugt
发明人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan Van de Winkel , Martine Van Vugt
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2854 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S435/81
摘要： This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
摘要翻译： 本发明涉及抗P-选择素抗体，特别涉及含有源自人源的Fc部分并且不结合补体因子C1q的抗P-选择素抗体及其变体。 这些抗体具有新的和本发明的性质，为患有严重肢体缺血或外周动脉闭塞性疾病（CLI / PAOD）的患者带来益处。
-
公开(公告)号：US07754867B2
公开(公告)日：2010-07-13
申请号：US12481623
申请日：2009-06-10
申请人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
发明人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
CPC分类号： C07K16/2854 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S435/81
摘要： This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
摘要翻译： 本发明涉及抗P-选择素抗体，特别涉及含有源自人源的Fc部分并且不结合补体因子C1q的抗P-选择素抗体及其变体。 这些抗体具有新的和本发明的性质，为患有严重肢体缺血或外周动脉闭塞性疾病（CLI / PAOD）的患者带来益处。
-
公开(公告)号：US20090311779A1
公开(公告)日：2009-12-17
申请号：US12481623
申请日：2009-06-10
申请人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
发明人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
CPC分类号： C07K16/2854 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S435/81
摘要： This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
摘要翻译： 本发明涉及抗P-选择素抗体，特别涉及含有源自人源的Fc部分并且不结合补体因子C1q的抗P-选择素抗体及其变体。 这些抗体具有新的和本发明的性质，为患有严重肢体缺血或外周动脉闭塞性疾病（CLI / PAOD）的患者带来益处。
-
公开(公告)号：USRE44359E1
公开(公告)日：2013-07-09
申请号：US13471899
申请日：2012-05-15
申请人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Braemer , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
发明人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Braemer , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
CPC分类号： C07K16/2854 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S435/81
摘要： This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
摘要翻译： 本发明涉及抗P-选凝素抗体，特别涉及含有源自人源的Fc部分并且不结合补体因子C1q的抗P-选择蛋白抗体及其变体。 这些抗体具有新的和本发明的性质，为患有严重肢体缺血或外周动脉闭塞性疾病（CLI / PAOD）的患者带来益处。
-
公开(公告)号：US07601752B2
公开(公告)日：2009-10-13
申请号：US11593821
申请日：2006-11-06
申请人： Lilli Anselm , Katrin Groebke Zbinden , Wolfgang Haap , Hans Hilpert , Jacques Himber , Bernd Kuhn , Narendra Panday , Fabienne Ricklin , Stefan Thomi
发明人： Lilli Anselm , Katrin Groebke Zbinden , Wolfgang Haap , Hans Hilpert , Jacques Himber , Bernd Kuhn , Narendra Panday , Fabienne Ricklin , Stefan Thomi
IPC分类号： A61K31/4025 , C07D409/12
CPC分类号： C07D409/14 , C07D413/14
摘要： The invention is concerned with novel pyrrolidine derivatives of formula (I) wherein X, Y, R1, R2 and R3 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
摘要翻译： 本发明涉及式（I）的新型吡咯烷衍生物，其中X，Y，R 1，R 2和R 3如说明书和权利要求书中所定义，以及其生理上可接受的盐。 这些化合物抑制凝血因子Xa，并且可以用作药物。
-
公开(公告)号：US6034275A
公开(公告)日：2000-03-07
申请号：US762827
申请日：1996-12-06
申请人： Johannes Aebi , Henrietta Dehmlow , Jacques Himber , Synese Jolidon , Hans Lengsfeld , Olivier Morand , Gerard Schmid , Ku-Hua Ji
发明人： Johannes Aebi , Henrietta Dehmlow , Jacques Himber , Synese Jolidon , Hans Lengsfeld , Olivier Morand , Gerard Schmid , Ku-Hua Ji
IPC分类号： C07D249/08 , A61K31/135 , A61K31/15 , A61K31/165 , A61K31/275 , A61K31/35 , A61K31/351 , A61K31/38 , A61K31/381 , A61K31/40 , A61K31/44 , A61K31/4402 , A61K31/4418 , A61K31/445 , A61P3/06 , A61P9/00 , A61P31/04 , A61P31/10 , C07C211/08 , C07C211/15 , C07C211/16 , C07C217/20 , C07C217/46 , C07C217/52 , C07C217/76 , C07C225/22 , C07C235/78 , C07C235/84 , C07C237/06 , C07C255/56 , C07C255/58 , C07C311/04 , C07C317/16 , C07C323/10 , C07C323/22 , C07C323/25 , C07D207/08 , C07D211/46 , C07D211/58 , C07D213/64 , C07D233/60 , C07D257/04 , C07D309/12 , C07D333/20 , C07D333/22 , C07C213/00
CPC分类号： C07C323/25 , C07C217/20 , C07C217/46 , C07C217/52 , C07C235/78 , C07C235/84 , C07C255/56 , C07C311/04 , C07C323/22 , C07D211/46 , C07D211/58 , C07D213/64 , C07D333/22 , C07C2101/02
摘要： Tertiary amines of the formula ##STR1## wherein A.sup.1, A.sup.2, A.sup.3, A.sup.4, L, M, p, T, and Q are as defined herein, have antimycotic and cholesterol-lowering activity.
摘要翻译： 下式的叔胺其中A1，A2，A3，A4，L，M，p，T和Q如本文所定义，具有抗真菌和降低胆固醇的活性。
-
公开(公告)号：US4801617A
公开(公告)日：1989-01-31
申请号：US154267
申请日：1988-02-10
申请人： Gerard LeClerc , Didier Huber , Jacques Himber , Guy Andermann
发明人： Gerard LeClerc , Didier Huber , Jacques Himber , Guy Andermann
IPC分类号： C07D233/22 , C07D233/50 , A61K31/415
CPC分类号： C07D233/22 , C07D233/50
摘要： Antiglaucoma compounds having beta adrenoreceptor antagonist properties and alpha adrenoreceptor antagonist properties are described. The compounds comprise a beta blocker-derived moiety designed to provide beta antagonist properties and an imidazolidine moiety designed to provide alpha-antagonist properties. Methods of synthesizing the compounds are also described. The compounds are useful in the treatment of glaucoma due to their ability to lower elevated intraocular pressure.
摘要翻译： 描述了具有β肾上腺素受体拮抗剂特性和α肾上腺素受体拮抗剂性质的抗青光眼化合物。 该化合物包含设计用于提供β拮抗剂特性的β阻断剂衍生部分和设计用于提供α-拮抗剂性质的咪唑烷部分。 还描述了合成化合物的方法。 由于其降低眼内压升高的能力，这些化合物可用于治疗青光眼。
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.045 秒)
